How should a child with rhabdomyosarcoma who just completed his final chemotherapy and same‑day radiotherapy, with recent imaging showing no disease, be evaluated and managed after a seizure?

Immediate Management of Post-Treatment Seizure in Pediatric Rhabdomyosarcoma

This child requires urgent neuroimaging with contrast-enhanced MRI to rule out treatment-related complications, immediate seizure control with benzodiazepines followed by levetiracetam, and initiation of secondary anticonvulsant prophylaxis. 1

Acute Seizure Management

Stabilize the patient immediately by assessing circulation, airway, and breathing (CAB) and obtaining a rapid blood glucose measurement as the first step. 1

First-Line Seizure Control

• Administer lorazepam 0.1 mg/kg IV (maximum 2 mg) for active convulsive seizures. 1
• A second dose may be given after ≥1 minute if seizures continue, up to two total doses. 1
• Add levetiracetam 40 mg/kg IV bolus immediately after benzodiazepine administration. 1

Refractory Seizures

• If seizures persist despite initial therapy, add phenobarbital 10–20 mg/kg IV loading dose (maximum 1 g) and arrange immediate transfer to the pediatric intensive care unit. 1
• Initiate continuous EEG monitoring for refractory seizures. 1

Urgent Diagnostic Evaluation

Neuroimaging Priority

Obtain contrast-enhanced cerebral MRI urgently to exclude critical treatment-related complications. 1 This imaging is essential because:

• Treatment-associated neurotoxicity from recent chemotherapy and same-day radiotherapy is a primary concern. 1
• Cerebral edema from radiation therapy may develop acutely and requires immediate identification. 1
• Intracranial hemorrhage or ischemia must be ruled out. 1
• Infectious complications are possible given chemotherapy-induced immunosuppression. 1
• Metabolic disturbances can precipitate seizures. 1
• Rare CNS involvement by rhabdomyosarcoma, though uncommon, must be excluded despite recent clear imaging. 1, 2

MRI is superior to CT for detecting brain abnormalities in children with seizures, identifying pathology in 28.2% of cases not seen on initial CT. 3

Electroencephalography

• Obtain a standard EEG to rule out non-convulsive status epilepticus, assess future seizure risk, and differentiate other causes of altered mental status. 1
• EEG is critical for distinguishing epileptic seizures from other neurological complications. 3

Laboratory Workup

Order the following tests to identify metabolic derangements:

• Complete blood count 1
• Comprehensive metabolic panel 1
• Serum magnesium, calcium, and phosphate 1
• Blood and cerebrospinal fluid analysis if infectious etiology is suspected 1

Maintenance Anticonvulsant Therapy

After seizure resolution, initiate secondary prophylaxis because the vast majority of brain tumor patients who experience a seizure should receive at least transient anticonvulsant therapy. 3

Recommended Dosing Regimen

• Lorazepam 0.05 mg/kg IV every 8 hours for three doses 1
• Levetiracetam 30 mg/kg IV every 12 hours (or increase prophylactic dose by 10 mg/kg to a total of 20 mg/kg every 12 hours, maximum 1,500 mg) 1
• Phenobarbital 1–3 mg/kg IV every 12 hours if additional seizure control is needed 1

Anticonvulsant Selection Rationale

Levetiracetam is the preferred first-line agent for this patient. 1, 3 The evidence strongly supports this choice because:

• It demonstrates superior efficacy and good tolerability compared to older agents. 1
• It lacks interactions with chemotherapy agents and does not induce hepatic metabolism, which is critical given recent chemotherapy completion. 1, 3
• Psychiatric side effects, while possible, are manageable. 1, 3
• Physicians may consider levetiracetam over older AEDs to reduce side effects (Level C recommendation). 3

Agents to Avoid

Do not use first-generation anticonvulsants (phenytoin, carbamazepine, phenobarbital as primary therapy) because they have significant drug-interaction risk with steroids and chemotherapy. 1, 3

Avoid valproic acid in females of childbearing potential and monitor closely for drug interactions if used. 1, 3

Lamotrigine is unsuitable for acute management because it requires several weeks to reach therapeutic levels. 1, 3

Management of Treatment-Related Complications

Radiation-Induced Cerebral Edema

If MRI demonstrates cerebral edema from same-day radiotherapy:

• Administer dexamethasone 4–16 mg/day with rapid taper to the lowest effective dose. 1, 3
• Limit steroid duration to minimize toxicity including immunosuppression, metabolic disturbances, and impaired wound healing. 1, 3

Chemotherapy-Related Neurotoxicity

Recent chemotherapy completion raises concern for:

• Direct neurotoxicity from chemotherapeutic agents 1
• Posterior reversible encephalopathy syndrome (PRES) as a possible complication 1

Infection Risk

Chemotherapy-induced immunosuppression significantly raises the risk of CNS infections. 1

Provide Pneumocystis jirovecii pneumonia prophylaxis with trimethoprim-sulfamethoxazole if steroid therapy exceeds four weeks or lymphocyte count falls below 1,000 cells/µL. 1

Critical Pitfalls to Avoid

Do not assume this seizure is benign simply because recent imaging showed no cancer; post-treatment seizures often signal treatment-related complications requiring targeted intervention. 1

Do not delay urgent MRI in new-onset seizures in cancer patients, as this is essential for identifying treatable complications. 1, 3

Do not use prophylactic anticonvulsants without a documented seizure; evidence shows no benefit in preventing a first seizure (Level A recommendation). 3, 1

Avoid enzyme-inducing anticonvulsants that interfere with chemotherapy metabolism. 1, 3

Do not continue steroids longer than necessary to avoid significant toxicity. 1, 3

Follow-Up and Monitoring

• Continue levetiracetam at maintenance dosing during the prophylaxis period. 1
• Monitor serum drug levels to assess adherence and detect side effects. 1
• Consider tapering anticonvulsants when MRI shows no structural abnormality and treatment-related complications have resolved. 1
• Repeat neuroimaging if seizure control deteriorates, as this may indicate disease progression or new complications. 1, 3
• Inquire about seizure activity at each follow-up visit. 1
• Provide education to patients and caregivers on seizure management and emergency contact procedures. 1